This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Accelrys And Pfizer Extend Agreement For Global Deployment Of Scientific Innovation Lifecycle Management Software

SAN DIEGO, May 7, 2013 /PRNewswire/ -- Accelrys, Inc. (NASDAQ: ACCL), a leading provider of scientific innovation lifecycle management software, announced today that Pfizer, Inc. (NYSE: PFE) has signed a three-year contract with Accelrys, extending the companies' long-standing strategic partnership.  The agreement continues the global deployment of the Accelrys Enterprise Platform, Pipeline Pilot, Cheminformatics Suite and Modeling & Simulation software to Pfizer researchers worldwide.

(Logo:  http://photos.prnewswire.com/prnh/20120416/MM88629LOGO)

The scientifically aware Accelrys Enterprise Platform offers access to broad scientific informatics solutions across different domains while simplifying integration into existing IT environments. The Pipeline Pilot scientific workflow authoring application enables scientific services that automate the process of accessing, analyzing and reporting scientific data for sharing across the scientific community. Leveraging the Accelrys Cheminformatics Suite, scientists can register, search, mine, analyze and report on chemical structures and reactions, chemically modified sequences and associated information such as inventory, assay and analytical results. Accelrys Modeling and Simulation software accelerates collaborative research and development of innovative health care treatments through the use of predictive science.

Accelrys President and Chief Executive Officer Max Carnecchia described the profound challenges that are requiring pharmaceutical companies to transform their businesses to remain competitive, saying, "From externalization to cost pressures to regulatory compliance, today's industry trends are making it more difficult for pharmaceutical organizations to deliver innovative products to market quickly and cost-effectively. As Pfizer well knows, overcoming these challenges demands both disease area and technology expertise. Accelrys' integrated technology solutions ― built with deep scientific understanding ― are helping valued customers like Pfizer grow their businesses to meet the demands of today and tomorrow."

About Accelrys, Inc.Accelrys (NASDAQ:ACCL), a leading provider of scientific innovation lifecycle management software, supports industries and organizations that rely on scientific innovation to differentiate themselves. The industry-leading Accelrys Enterprise Platform provides a broad, flexible scientific solution optimized to integrate the diversity of science, experimental processes and information requirements across the research, development, process scale-up and early manufacturing phases of product development. By incorporating capabilities in applications for modeling and simulation, enterprise lab management, workflow and automation, and data management and informatics, Accelrys enables scientific innovators to access, organize, analyze and share data in unprecedented ways, ultimately enhancing innovation, improving productivity and compliance, reducing costs and speeding time from lab to market.

Accelrys solutions are used by more than 1,300 companies in the pharmaceutical, biotechnology, energy, chemicals, aerospace, consumer packaged goods and industrial products industries. Headquartered in San Diego, Calif., Accelrys employs more than 200 full-time PhD scientists. For more information about Accelrys, visit www.accelrys.com.

Related Links Accelrys Website Follow Accelrys on Twitter Friend Accelrys on Facebook Accelrys' YouTube Channel Connect with Accelrys on LinkedIn

SOURCE Accelrys, Inc.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs